Crossmark

Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab

Crossref DOI link: https://doi.org/10.1007/s10147-023-02370-6

Published Online: 2023-06-22

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nagaoka, Tomoyuki

Osumi, Hiroki

Ueno, Teruko

Ooki, Akira

Wakatsuki, Takeru

Nakayama, Izuma

Ogura, Mariko

Takahari, Daisuke

Chin, Keisho

Matsueda, Kiyoshi

Yamaguchi, Kensei

Shinozaki, Eiji https://orcid.org/0000-0002-7448-5894
License Information

Text and Data Mining valid from 2023-06-22

Version of Record valid from 2023-06-22
More Information

Article History

Received: 14 March 2023

Accepted: 8 June 2023

First Online: 22 June 2023

Declarations

:

: The authors declare that they have no conflict of interest.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of The Cancer Institute Hospital of JFCR (No. 2017-GA-1123) with a waiver of informed consent from patients, given its retrospective nature.

: The protocol was described on the hospital website, and participants had the opportunity to opt out of the study; no additional consent was required from the patients.

Document is current

Any future updates will be listed below